Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging (NCT07216352) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Evaluate the Safety and Efficacy of a Topical Serum (AGE Serum) in Improving Visible Signs of Aging
United States25 participantsStarted 2025-10-25
Plain-language summary
The primary objective is to evaluate the safety and efficacy of a topical serum (AGE serum) in improving visible signs of aging (e.g., fine lines, wrinkles, sagging, texture, radiance) on the full face and neck.The study will be conducted in non-menopausal female and male subjects who are on glucagon-like peptide-1 (GLP-1) agonist therapy for weight loss.
Who can participate
Age range25 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Presence of mild to moderate signs of facial aging (e.g., fine lines, laxity, dull texture) based on modified Griffith scale.
✓. Adult men and women aged 25-50 years.
✓. Fitzpatrick skin types I-IV.
✓. Current treatment with a stable dose of GLP-1 agonist medication, including Ozempic, Rybelsus, or Wegovy for at least last 6 months.
✓. Must be willing to sign a photography release and ICF, and complete the entire course of the study.
✓. Subjects in good general health based on the investigator's judgment and medical history.
✓. Negative urine pregnancy test result at the time of study entry (if applicable).
✓. Subjects of childbearing potential must agree to use an effective method of birth control during the entire course of the study. All systemic birth control measures must be in consistent use for at least 30 days prior to study enrollment.
Exclusion criteria
✕. Pregnancy or planned pregnancy during the study or currently breastfeeding.
✕. Current menopausal state.
✕. Any uncontrolled systemic disease.
✕. Current use of other GLP-1 agonist therapy aside from the GLP-1 agonist class of medications (Ozempic, Rybelsus, or Wegovy).
✕. History of autoimmune connective tissue disease.
✕. Current use of immunosuppressive medication.
✕. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
✕. Active dermatitis or active infection in the proposed treatment area.